CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

[February 28, 2014]

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/23gc8x/pharmapoint) has announced the addition of the "PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022" report to their offering.

HCV Market Is Expected to Grow During the Forecast Period The HCV market generated approximately $4.0 billion from global sales in 2012. Over the next 10 years, this market is expected to grow to reach $10.8 billion, with major growth occurring in the main HCV markets, such the US.

Some of the main drivers of growth are expected to be: - Introduction of interferon-free HCV regimens, which have an improved side effect profile compared with current HCV therapies - Increase in patient awareness of HCV through screening initiatives and public awareness campaigns - A paradigm shift toward preventive care of HCV in most countries The barriers limiting the growth of the market include: - Limited patient awareness regarding the threat of HCV - Concerns over decreasing healthcare costs as part of government austerity measures Pharma Giants Battle as New Entrants Leverage Next-Generation HCV Regimens to Capture Market Share Roche and Merck have been the HCV market leaders for the better part of two decades. The companies leveraged their interferon and ribavirin drugs to quickly capture market share. Roche's and Merck's commitment to innovation resulted in the launch of peginterferon HCV therapies, which quickly overtook the market, but both companies fell behind in the race to develop direct-acting antiviral (DAA) therapies for HCV.

This enabled Vertex to establish itself as the leader in the US through with the launch of Incivek (telaprevir). Janssen was also able to capitalize on the demand for DAAs to become the front-runner in many European markets through the launch of Incivo (telaprevir).

The authors anticipates that the launch of next-generation HCV regimens will continue to enable new entrants, such as Gilead, AbbVie, Bristol-Myers Squibb, and Boehringer Ingelheim, to capture market share. Companies with interferon-free regimens are expected to quickly capture market share in the US, Japan, and many European countries.

New Entrants Welcomed in the Market after the Launch of Next-Generation HCV Regimens There will still be demand for improved HCV therapies even after next-generation HCV therapies have overtaken the market. Most late-stage HCV regimens are focused on treating HCV genotype 1 infection since it is the most prevalent strain, but there is demand for therapies with pan-genotypic activity. A regimen that is well tolerated, effective against all HCV genotypes, and requires less than 12 weeks of therapy will likely steal patient share from the next-generation HCV therapies that are included in this forecast.

Launch of Interferon-Free Regimens Will Fundamentally Change the HCV Treatment Algorithm in the US, Japan, and Many European Countries AbbVie's combination therapy (ABT-450, ABT-333, and ABT-267) is expected to be among the first interferon-free HCV regimens to launch in several countries. The regimen's tolerability, efficacy in both treatment-na?ve and treatment-experienced patients, and short duration of therapy are expected to result in it becoming a front-line therapy. The authors forecasts peak year sales for the regimen of $3.1 billion in 2018.

Gilead's fixed-dose, single-pill HCV regimen, sofosbuvir/ledipasvir, is forecast to launch in most countries shortly after the first of the interferon-free therapies. The ability of the sofosbuvir/ledipasvir regimen to be safe and effective without co-administration with ribavirin is expected to result in the drug becoming the standard of care in many markets. The authors anticipates peak year sales for sofosbuvir/ledipasvir of $4.3 billion in 2019.

Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - AbbVie - Boehringer Ingelheim - Bristol-Myers Squibb - Gilead - Janssen - Merck - Roche - Vertex For more information visit http://www.researchandmarkets.com/research/23gc8x/pharmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

CONTACT: Research and Markets, Laura Wood, Senior Manager.

press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Infectious Diseases (http://www.researchandmarkets.com/categories.asp?cat_id=121&campaign_id=23gc8x) .

(c) 2014 M2 COMMUNICATIONS

[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter